BRIEF published on 06/12/2025 at 11:05, 1 year 4 months ago Relief Therapeutics Announces Results of Annual General Meeting Financial Statements Shareholder Approval Annual Meeting Board Elections Compensation Approval
BRIEF published on 06/12/2025 at 11:05, 1 year 4 months ago Relief Therapeutics annonce les résultats de son assemblée générale annuelle États Financiers Réunion Annuelle Approbation Des Actionnaires Élections Du Conseil D'administration Approbation De L'indemnisation
PRESS RELEASE published on 06/12/2025 at 11:00, 1 year 4 months ago Relief Therapeutics Announces Results of Annual General Meeting Relief Therapeutics announces results of its Annual General Meeting with shareholders approving all proposals by a large majority. AGM covers key agenda items and re-election of board members and auditors Board Of Directors Annual General Meeting Shareholders Relief Therapeutics AGM Results
BRIEF published on 05/22/2025 at 07:05, 1 year 5 months ago Relief Therapeutics Secures FDA Rare Pediatric Disease Designation for RLF-TD011 FDA Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Rare Pediatric Disease
BRIEF published on 05/22/2025 at 07:05, 1 year 5 months ago Relief Therapeutics obtient la désignation de maladie pédiatrique rare de la FDA pour le RLF-TD011 FDA THÉRAPEUTIQUE DE SECOURS RLF-TD011 Epidermolyse Bulleuse Maladie Pédiatrique Rare
PRESS RELEASE published on 05/22/2025 at 07:00, 1 year 5 months ago Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 Relief Therapeutics granted FDA Rare Pediatric Disease Designation for RLF-TD011 in treating epidermolysis bullosa, a rare genetic skin disorder. Potent antimicrobial & anti-inflammatory activity shown FDA Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Rare Pediatric Disease Designation
BRIEF published on 05/15/2025 at 07:05, 1 year 5 months ago Relief Therapeutics Announces 2025 AGM Agenda Annual General Meeting Financial Statements Shareholder Voting Board Re-election Compensation Approval
BRIEF published on 05/15/2025 at 07:05, 1 year 5 months ago Relief Therapeutics annonce l'ordre du jour de l'assemblée générale annuelle 2025 États Financiers Assemblée Générale Annuelle Réélection Du Conseil D'administration Vote Des Actionnaires Approbation De L'indemnisation
PRESS RELEASE published on 05/15/2025 at 07:00, 1 year 5 months ago Relief Therapeutics Publishes 2025 Annual General Meeting Agenda Relief Therapeutics announces agenda for its 2025 Annual General Meeting featuring key resolutions and re-elections. Meeting scheduled for June 12 in Geneva, Switzerland Shareholders Switzerland Relief Therapeutics Agenda 2025 Annual General Meeting
BRIEF published on 04/10/2025 at 07:05, 1 year 6 months ago Relief Therapeutics Announces 2024 Financial Results and Strategic Progress Biopharmaceutical Relief Therapeutics Rare Diseases 2024 Financial Results Pipeline Progress
Published on 10/28/2026 at 08:00, 1 hour 48 minutes ago Algo Grande Copper Makes New Skarn Discovery at Adelita; Step-Out Hole AG-CG-PH2-003 Returns a Combined 139.81 Metres of 1.3% CuEq from Cerro Grande and the New Margarita Skarn
Published on 10/28/2026 at 02:55, 6 hours 53 minutes ago Challenger Underground MRE Doubles to 230koz @ 3.65 g/t Au
Published on 10/28/2026 at 02:50, 6 hours 58 minutes ago Letter to Shareholders Regarding Annual General Meeting
Published on 10/27/2026 at 23:40, 10 hours 8 minutes ago Second Closing of US$3.4 Million Private Placement
Published on 10/27/2026 at 23:25, 10 hours 23 minutes ago Gamma Resources Announces Leadership Transition: C. Connor Messler to Become Chief Executive Officer and Gabriel Alonso-Mendoza to Become Chairman; Grants Incentive Stock Options
Published on 10/28/2026 at 09:36, 12 minutes ago Original-Research: Villeroy & Boch AG (von Quirin Privatbank Kapitalmarktgeschäft): Buy
Published on 10/28/2026 at 09:35, 12 minutes ago Farizon SV Model Year 2027 makes its French debut at Rungis, tested for real-world delivery
Published on 10/28/2026 at 09:25, 23 minutes ago Jacobi launches the Investment Management Harness, a governed path from AI prototype to production
Published on 10/28/2026 at 09:15, 33 minutes ago CELSET Launches SOLTOX, a Korean Botulinum Toxin Type A Brand, for International Markets
Published on 10/28/2026 at 09:05, 42 minutes ago Rivermate recognized as a key provider of EoR solutions in Everest Group's Employer of Record (EoR) Solutions PEAK Matrix® Assessment 2026
Published on 10/28/2026 at 08:00, 1 hour 48 minutes ago Edenred successfully raises €800 million in a dual-tranche bond offering
Published on 10/28/2026 at 08:00, 1 hour 48 minutes ago Edenred lève avec succès 800 millions d’euros dans le cadre d’une émission obligataire à deux tranches
Published on 10/27/2026 at 18:00, 15 hours 48 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 22, 2026
Published on 10/27/2026 at 18:00, 15 hours 48 minutes ago Nombre total de droits de vote et actions composant le capital social au 22 octobre 2026
